US2006040358A1PendingUtilityA1
IGF-1 receptor interacting proteins
Est. expiryDec 3, 2018(expired)· nominal 20-yr term from priority
C07K 14/4702A61K 38/1709A61P 35/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention comprises a nucleic acid molecule with the sequence SEQ ID NO:5 and the complementary sequence, and its use in diagnosis and therapy. This nucleic acid molecule (IIP-10) is a gene which encodes an IGF-1 receptor binding polypeptide.
Claims
exact text as granted — not AI-modified1 . A method for the production of a therapeutic agent for the treatment of carcinomas in a patient comprising combining a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound which modulates the interaction between IGF-1R and IIP-10 in a cellular assay, whereby in said cellular assay tumor cells or cells transfected with expression constructs of IGF-1R and of said IIP are treated with said compound, and complex formation between IGF-1R and said respective IIP is analyzed, and the extent of said complex formation in the case of inhibition does not exceed 50% when referenced against100% for complex formation without said compound in said same cellular assay.
Join the waitlist — get patent alerts
Track US2006040358A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.